

Caron Modeas

Acknowledgements for Editing/Writing Expertise

Book Chapters:

Cost-Effectiveness Analysis (Author: H. Bang) in: Encyclopedia of Biopharmaceutical Statistics, 4th Ed, Vol 1-4; S-C Chow, Ed. CRC Press, Taylor and Francis Group, Boca Raton, FL; 2018.

Articles:

Bang H. Biomarker Score in Risk Prediction: Beyond Scientific Evidence and Statistical Performance. *Diabetes Metab J.* 2020; 44:245-247.

Lee H, Lee Y-h, Kim SU, Kim HC. Metabolic Dysfunction-associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: a Nationwide Cohort Study. *Clin Gastro Hepatol.* 2020 [In Press].
<https://doi.org/10.1016/j.cgh.2020.12.022>.

Bae J, Hong N, Lee B-W, Kang ES, Cha B-S, Lee Y-H. Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis. *J Clin Med.* 2020; 9(3):798. <https://doi.org/10.3390/jcm9030798>.

Lee HH, Cho Y, Choi YJ, *et al.* Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study. *Cardiovasc Diabetol.* 2020; 19(81):1-11.
<https://doi.org/10.1186/s12933-020-01064-x>

Lee H, Kim G, Choi YJ, Huh BW, Lee B-W, Kang ES, Cha B-S, Lee EJ, Lee Y-H, Huh KB. Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus. *Diabetes Metab J.* 2020; 44:267-276. <https://doi.org/10.4093/dmj.2019.0001>.

Kim SR, Lee SG, Kim SH, *et al.* SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. *Nat Commun.* 2020; 11(2127):1-11.
<https://doi.org/10.1038/s41467-020-15983-6>.

Lee JY, Han K, Han E, Kim G, Cho H, Kim KJ, Lee BW, Kang ES, Cha B-S, Brayne C, Lee Y-h. Risk of Incident Dementia According to Metabolic Health and Obesity Status in Late Life: A Population-Based Cohort Study. *J Clin Endocrinol Metab.* 2019; 104(7):2942–2952. doi: 10.1210/jc.2018-01491.

Lee Y-h, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, Rhee EJ. Nonalcoholic fatty liver disease in diabetes. Part I: Epidemiology and diagnosis. *Diabetes Metab J.* 2019; 43(1):31-45.
<https://doi.org/10.4093/dmj.2019.0011>

Yim J, Kim G, Lee B-W, Kang ES, Cha B-S, Kim J-H, Cho JW, Lee S-G, Lee Y-h. Relationship Between Circulating Netrin-1 Concentration, Impaired Fasting Glucose, and Newly Diagnosed Type 2 Diabetes. *Front Endocrinol.* 2018; 23. <https://doi.org/10.3389/fendo.2018.00691>.

Lee EY, Kang B, Yang Y, Yang HK, Kim H-S, Lim S-Y, Lee J-H, Lee S-S, Suh B-K, Yoon K-H. Study Time after School and Habitual Eating Are Associated with Risk for Obesity among Overweight Korean Children: A Prospective Study. *Obes Facts*. 2018; 11:46-55. <https://doi.org/10.1159/000486132>.

Lee EY, Lee Y-h, Yi S-W, Shin S-A, Yi J-J. BMI and All-Cause Mortality in Normoglycemia, Impaired Fasting Glucose, Newly Diagnosed Diabetes, and Prevalent Diabetes: A Cohort Study. *Diabetes Care*. 2017; 40(8):1026-1033. <https://doi.org/10.2337/dc16-1458>.

Kinon BJ, Liu-Seifert H, Stauffer VL, Jacob J. Bone Loss Associated with Hyperprolactinemia in Patients with Schizophrenia: Are There Gender Differences? *Clin Schizo Rel Psychoses*. 2013; Fall:115-123.

Case M, Stauffer VL, Ascher-Svanum H, *et al*. The heterogeneity of antipsychotic response in the treatment of schizophrenia. *Psychol Med*. 2011; 41(6):1291-1300. doi:10.1017/S0033291710001893.

Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, Zhu B, Ojeh CK, Baker BA, Effron MB. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes Mellitus (OPTIMUS)-3 Trial. *Eur Heart J*. 2011; 32(7):838-846. <https://doi.org/10.1093/eurheartj/ehq494>.

Ruberg SJ, Chen L, Stauffer V, *et al*. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia. *BMC Psychiatry*. 2011; 11(23):1-11. <https://doi.org/10.1186/1471-244X-11-23>.

Seftel A, Goldfischer E, Kim ED, Dula E, Zeigler H, Burns P. Onset of Efficacy of Tadalafil Once Daily in Men With Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Trial. *J Urology*. 2011; 185(1):243-248. <https://doi.org/10.1016/j.juro.2010.09.035>.

Degenhardt EK, Jamal HH, Tormey S, Case M. Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: an analysis of 2 adult studies in treatment-resistant depression. *J Clin Psychopharmacol*. 2011; 31(3):337-340.

Sontag A, Wickerham L, Ni X, Mitchell BB, Helt C, Muram D. Estimated Risk of Invasive Breast Cancer in Postmenopausal Women with and Without Family History of the Disease. *Menopause*. 2011; 18(5):515-520.

Houston JP, Ketter TA, Case M, Bowden C, Degenhardt EK, Jamal HH, Tohen M. Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodes. *J Psych Res*. 2011; 45(2):169-173.

Fijal B, Perlis RH, Heinloth AN, Houston JP. The Association of Single Nucleotide Polymorphisms in the Catechol-O-Methyltransferase Gene and Pain Scores in Female Patients With Major Depressive Disorder. *J Pain*. 2010; 11(9):910-915. doi:10.1016/j.jpain.2009.12.016.

Schwartz SL, Ignaut DA, Bodie JN. Humalog® KwikPen™: an insulin-injecting pen designed for ease of use. *Exp Rev Med Dev*. 2010; 7(6):735-743. DOI: 10.1586/erd.10.63.

Kinon B, Chen L, Ascher-Svanum, H, *et al*. Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia. *Neuropsychopharmacol*. 2010; 35:581-590. <https://doi.org/10.1038/npp.2009.164>

Case M, Treuer T, Karagianis J, *et al*. The potential role of appetite in predicting weight changes during treatment with olanzapine. *BMC Psychiatry*. 2010; 10:72.

Lobo ED, Robertson-Plouch C, Quinlan T, Hong Q, Bergstrom R. Oral olanzapine distribution in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model. *Pediatric Drugs*. 2010; 12(3):201-211.

Pearman L, Kagan R, Arsenault J, Muram D. The Effects of Raloxifene on Mammographic Breast Density: a Review of Clinical Trials. *Menopause*. 2010; 17(3):654-659.

Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic Options for Treatment-resistant Depression. *CNS Drugs*. 2010; 24(2):131-161. Svanum H, Kollack-Walker S, Jacob J, Kapur S. Early onset of antipsychotic action in schizophrenia: evaluation the possibility of shorter acute efficacy trials. *J Clin Psychopharmacol*. 2010; 30(3):286-289.

Wenger NK, Mischke JM, Schroeder R, Schroeder K, Collins P, Grady D, Kornitzer M, Mosca L, Barrett-Connor E. Electrocardiograms of Menopausal Women With Coronary Heart Disease or at Increased Risk for Its Occurrence. *Am J Cardiol*. 2010; 106(11): 1580-1587. DOI: 10.1016/j.amjcard.2010.07.032.

Houston JP, Gatz JL, Degenhardt EK, *et al*. Symptoms predicting remission after divalproex augmentation with olanzapine in partially nonresponsive patients experiencing mixed bipolar I episode: a post-hoc analysis of a randomized controlled study. *BMC Res Notes*. 2010; 3(276): 1-6. <https://doi.org/10.1186/1756-0500-3-276>.

Stauffer VL, Lipkovich I, Hoffmann VP, *et al*. Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. *BMC Psychiatry*. 2009; 9(12):1-11. <https://doi.org/10.1186/1471-244X-9-12>.

Ignaut, DA, Schwartz SL, Sarwat S, Murphy HL. Comparative Device Assessments: Humalog KwikPen Compared With Vial and Syringe and FlexPen. *Diabetes Ed*. 2009; 35(5):789-798. DOI: 10.1177/0145721709340056.

Fishbain DA, Hall JA, Risser RC, Gonzales JS. Does Pain Cause the Perception of Fatigue in Patients with Chronic Pain? Findings from Studies for Management of Diabetic Peripheral Neuropathic Pain with Duloxetine. *Pain Practice*. 2009; 9(5): 354-362.

Adler LA, Rubin R, Qiao M, Heinloth AN, Durell TM. Patient characteristics and treatment response to atomoxetine in adults with ADD versus ADHD comorbid with social anxiety disorder. *J ADHD Rel Disorders*. 2009; 1(3):5-15.

Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta E, Kapczinski F, Goodwin GM, Suppes T, Sachs GS, Chengappa KNR, Grunze H, Mitchell PB, Kanba S, Berk M. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. *Bipolar Disorders*. 2009; 11(5):453-473. DOI: 10.1111/j.1399-5618.209.00726.x.

Stauffer V, Karagianis J, Sutton V, Ascher-Svanum H, Treuer T, Silva de Lima M, Ball T, Poole-Hoffmann V, Tohen M. Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in Randomized, Blinded Trials Comparing Olanzapine to Other Atypical Antipsychotics for Treatment of Schizophrenia. *Clin Schizophrenia Rel Psychoses*. 2008 July: 136-143.

Deberdt W, Lipkovich I, Heinloth AN, Liu L, Kollack-Walker S, Edwards SE, Hoffmann VP, Hardy TA. Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder. *Ther Clin Risk Manag*. 2008; 4(4): 713–720. doi: 10.2147/tcrm.s3153.

Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, Monk BJ, Euland FR. Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study. *J Clin Oncol*. 2007; 25(5):526-531.

Monk BJ, Tian C, Rose PG, Lanciano R. Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials. *Gynecol Oncol*. 2007; 105(2):427-433. doi:10.1016/j.ygyno.2006.12.027.

Morse MA, Hobeika A, Osada T, Niedzwiecki D, Marcom PK, Blackwell KL, Anders C, Devi GR, Lyerly HK, Clay TM. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. *J Translat Med*. 2007; 5(42):1-9. doi:10.1186/1479-5876.

McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study. *Gynecol Oncol*. 2007; 105:508–516.

Waggoner SE, Darcy KM, Fuhrman B, Parham G, Lucci J III, Monk B, Moore D. Influence of smoking on progression-free and overall survival in women with stage IIB, III and IVA cervical carcinoma. *Gynecol Oncol*. 2006; 103(3):853-858.

McQuellon RP, Thaler H, Cella D, Moore DH. Quality of Life (QOL) Outcomes from a Randomized Trial of Cisplatin versus Cisplatin plus Paclitaxel for Women with Metastatic Cervical Cancer: Results from Gynecologic Oncology Group Study 169. *Gynecol Oncol*. 2006; 101-(2):296-304.

Mould DR, Fleming GF, Darcy KM, Spriggs D. Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. *Br J Clin Oncol*. 2006; 62(1):56-70. DOI:10.1111/j.1365-2125.2006.02718.x.

Long HJ III, Monk BJ, Huang HQ, Grendys EC Jr, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. *Gynecol Oncol*. 2006; 100(3):537-543. DOI:10.1016 / j.ygyno.2005.09.023.

Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, Rose GS, Spirtos NM. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. *Gynecol Oncol*. 2006; 102(3):432-439. DOI: 10.1016 / j.ygyno.2006.06.013.

Monk BJ, Im S, Wang J, Stock RJ, Peters WA III, Liu PY, Barrett RJ II, Berek JS, Souhami L, Grigsby P, Gordon W, Alberts DS. Rethinking the use of Chemotherapy and Radiation After Radical Hysterectomy: a Clinical-Pathological Analysis of SWOG 8797/GOG 109 by the Gynecologic Oncology Group. *Gynecol Oncol*. 2005; 96(3):721-728.

Long HJ, Blessing JA, Sorosky J. Phase II Trial of Dacarbazine, Mitomycin, Doxorubicin and Cisplatin with Sargramostim in Uterine Leiomyosarcoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2005; 99(2):339-342.

Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D. Quality-of-Life Comparisons in a Randomized Trial of Interval Secondary Cytoreduction in Advanced Ovarian Carcinoma: A Gynecologic Oncology Group Study. *J Clin Oncol*. 2005; 23(24):5605-5612. DOI: 10.1200/JCO.2005.08.147.

Greer BE, Bundy BN, Ozols RF, Fowler JM, Clarke-Pearson D, Burger RA, Mannel R, DeGeest K, Hartenbach EM, Baergen RN, Copeland LJ. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: A non-randomized comparison using an explanatory analysis: A Gynecologic Oncology Group study. *Gynecol Oncol*. 2005; 99(1):71-79. DOI:10.1016/j.ygyno.2005.05.0.

Monk BJ, Huang HQ, Cella D, Long HJ III. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. *J Clin Oncol*. 2005;23(21):4617-4625. DOI: 10.1200/JCO.2005.10.522.

Burger RA, Darcy KM, DiSaia PJ, Monk B, Grosen EA, Gatanaga T, Granger GA, Wang J, Tian C, Hanjani P, Cohn DE. Association between Serum Levels of Soluble Tumor Necrosis Factor Receptors/CA 125 and Disease Progression in Patients with Epithelial Ovarian Malignancy: A Gynecologic Oncology Group Study. *Cancer*. 2004; 101(1):106-115. DOI 10.1002/cncr.20314.

Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, et al. for the Gynecologic Oncology Group. Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma. *N Engl J Med.* 2004; 351:2489-2497. DOI 10.1056/NE/Moa041125.

Farley J, Smith LM, Darcy KM, Sobel E, O'Connor D, Henderson B, Morrison LE, Birrer MJ. Cyclin E Expression Is a Significant Predictor of Survival in Advanced, Suboptimally Debulked Ovarian Epithelial Cancers: A Gynecologic Oncology Group Study. *Cancer Res.* 2003; 63:1235-1241.

Graziano SL, Lee K, Propert KJ, Tinsley R, Hayes DM, Green M, Comis RL. Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: a Cancer and Leukemia Group B study. *Med Ped Oncology.* 1990; 18(1):22-26.

Kwiatkowski DJ, Propert KJ, Carey RW, Choi N, Green M. A phase II trial of cyclophosphamide, etoposide, and cisplatin with combined chest and brain radiotherapy in limited small-cell lung cancer: a Cancer and Leukemia Group B study. *J Clin Oncol.* 1987; 5(12):1874-1879.

Editorials:

Kim J, Bang H. Risks in Biomedical Science – Absolute, Relative, and Other Measures. *Dent Hypotheses.* 2020; 11:69-71.

Kim J, Bang H. Three common misuses of P values. *Dent Hypotheses.* 2016; 7:73-80.